Immunovant, Inc. (IMVT) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.32 M

Shareholding (Mar 2025)

FII

6.64%

Held by 138 FIIs

DII

68.5%

Held by 36 DIIs

Promoter

0.60%

How big is Immunovant, Inc.?

22-Jun-2025

As of Jun 18, Immunovant, Inc. has a market capitalization of $2.62 billion, with net sales of $0.00 million and a net profit of -$413.84 million over the last four quarters. The company reported shareholder's funds of $707.45 million and total assets of $777.32 million as of Mar 25.

What does Immunovant, Inc. do?

22-Jun-2025

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases, with a market cap of approximately $2.62 billion and a recent net profit of -$106 million. The company has no dividend yield and is currently loss-making.

Who are in the management team of Immunovant, Inc.?

22-Jun-2025

As of March 2022, the management team of Immunovant, Inc. includes Dr. Frank Torti (Chairman), Dr. Peter Salzmann (CEO), Dr. Eric Venker, and several independent directors: Andrew Fromkin, Douglas Hughes, George Migausky, and Atul Pande. They oversee the company's strategic direction and operations.

Is Immunovant, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Immunovant, Inc. shows a mildly bullish trend with positive momentum indicators, having outperformed the S&P 500 recently, despite mixed signals in some technical aspects.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,854 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.98

Return on Equity

-73.50%

Price to Book

4.69

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-121 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

37.19%

6 Months

48.38%

1 Year

-18.82%

2 Years

-43.5%

3 Years

56.06%

4 Years

201.45%

5 Years

-54.47%

Immunovant, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Immunovant, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Immunovant, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a mildly bullish stance for both weekly and monthly periods. Daily moving averages are bullish, suggesting positive momentum. However, the KST shows a mixed signal with a bullish weekly and bearish monthly reading. The Dow Theory indicates no trend in both weekly and monthly time frames. In terms of performance, Immunovant has outperformed the S&P 500 over the past week and month, with returns of 12.88% and 43.14%, respectively, compared to the S&P 500's 0.71% and 1.92%. However, it has underperformed over the year and five years. Overall, the current technical stance is mildly bullish, supported by several indicators, despite mixed signals in some areas....

Is Immunovant, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Immunovant, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and KST. However, the monthly MACD and KST are bearish, indicating mixed signals across time frames. The daily moving averages are mildly bearish, which tempers the overall bullish stance. The Dow Theory shows a mildly bullish position on both weekly and monthly charts, while the On-Balance Volume is also mildly bullish. In terms of returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 10.97% and 40.71% respectively, but has underperformed over the year and five years. Overall, the current stance is mildly bullish, driven primarily by the weekly indicators....

Is Immunovant, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Immunovant, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is bearish, indicating mixed signals across time frames. The Bollinger Bands are bullish on both weekly and monthly charts, supporting the mildly bullish stance. Moving averages show a mildly bearish signal on the daily chart, which contrasts with the overall trend. Dow Theory and OBV both indicate a mildly bullish position on the weekly and monthly time frames. In terms of performance, Immunovant has outperformed the S&P 500 over the past week and month, with returns of 30.31% and 51.04%, respectively, compared to 0.71% and 1.92% for the index. However, the year-to-date and one-year returns are negative at -0.36% and -15.65%, significantly lagging behind the S&P 500's gains of 16.30% and 19.89%. Overall, the current technical stance is mildly bulli...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-222.18%

EBIT to Interest (avg)

-258.75

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

0.22%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

68.47%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.05

EV to EBIT

-4.91

EV to EBITDA

-4.92

EV to Capital Employed

-334.97

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-58.50%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 69 Schemes (24.26%)

Foreign Institutions

Held by 138 Foreign Institutions (6.64%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -38.46% vs -17.86% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-127.10",
          "val2": "-94.20",
          "chgp": "-34.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-120.60",
          "val2": "-87.10",
          "chgp": "-38.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -59.58% vs -22.89% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-437.80",
          "val2": "-270.00",
          "chgp": "-62.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-12.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-413.80",
          "val2": "-259.30",
          "chgp": "-59.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-127.10

-94.20

-34.93%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-120.60

-87.10

-38.46%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -38.46% vs -17.86% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-437.80

-270.00

-62.15%

Interest

0.00

Exceptional Items

0.00

-12.50

100.00%

Consolidate Net Profit

-413.80

-259.30

-59.58%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -59.58% vs -22.89% in Mar 2024

All Annual Results

Company CV

About Immunovant, Inc.

Immunovant, Inc.

Pharmaceuticals & Biotechnology

Immunovant, Inc., formerly Health Sciences Acquisitions Corp, is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. It is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn).

Company Coordinates

Company Details

320 West 37Th Street , NEW YORK NY : 10018

Tel: 1 917 5803099

https://immunovant.com/

Registrar Details

Immunovant, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Immunovant, Inc.?

Watch in Real-Time

What does Immunovant, Inc. do?

Who are in the management team of Immunovant, Inc.?

Is Immunovant, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Immunovant, Inc. technically bullish or bearish?

Is Immunovant, Inc. technically bullish or bearish?

Is Immunovant, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Mar'25

About Immunovant, Inc.

Company Coordinates